ModifiedWellcare HawaiiPolicy CP.PHAR.97

Eculizumab (Soliris) Coverage Policy

Customize your policy alerts

Sign up for Wellcare Hawaii Policy CP.PHAR.97 alerts

Get alerted when Policy CP.PHAR.97 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity, prior authorization, initial and continued coverage, dosing, and exclusions for eculizumab (Soliris) for Commercial, HIM, and Medicaid members with PNH, aHUS, generalized myasthenia gravis, or AQP4-antibody-positive NMOSD.

Policy Summary

PayerWellcare Hawaii

PolicyEculizumab (Soliris) Coverage Policy

Policy CodePolicy N/A

Change TypeModified

Effective Date03.01.12

Next Review DateN/A

Key ActionSubmit clinical documentation demonstrating that all applicable initial approval criteria are met for the requested indication.

SourceLink

POLICY UPDATE CHANGES

The policy removed prior requirements related to Streptococcus pneumoniae and Haemophilus influenzae type b infections, age requirements, and meningococcal vaccination criteria.

The policy revised PNH and atypical hemolytic uremic syndrome criteria, including transfusion requirements and disease-specific clinical requirements.

The policy added generalized myasthenia gravis and neuromyelitis optica spectrum disorder as indications with approval criteria.

The policy added antiphospholipid syndrome and unspecified nephritic syndrome with other morphologic changes as excluded indications.

4FDA-approved covered disease indications

6 months

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedWellcare HawaiiPolicy CP.PHAR.97

Eculizumab (Soliris) Coverage Policy

Customize your policy alerts

Sign up for Wellcare Hawaii Policy CP.PHAR.97 alerts

Get alerted when Policy CP.PHAR.97 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerWellcare Hawaii

PolicyEculizumab (Soliris) Coverage Policy

Policy CodePolicy N/A

Change TypeModified

Effective Date03.01.12

Next Review DateN/A

Key ActionSubmit clinical documentation demonstrating that all applicable initial approval criteria are met for the requested indication.

SourceLink

POLICY UPDATE CHANGES

The policy removed prior requirements related to Streptococcus pneumoniae and Haemophilus influenzae type b infections, age requirements, and meningococcal vaccination criteria.

The policy revised PNH and atypical hemolytic uremic syndrome criteria, including transfusion requirements and disease-specific clinical requirements.

The policy added generalized myasthenia gravis and neuromyelitis optica spectrum disorder as indications with approval criteria.

The policy added antiphospholipid syndrome and unspecified nephritic syndrome with other morphologic changes as excluded indications.

4FDA-approved covered disease indications

6 months

Standard approval duration

4Unauthorized diagnoses or indication categories

1,200 mg q2wMaximum maintenance dose for aHUS, gMG, and NMOSD

2-point reductionRequired MG-ADL response for continued gMG therapy

300 mg/30 mLSingle-dose vial strength

Covered Indications and Exclusions

PNH Initial Therapy Criteria

Covered when ALL of the following are met for PNH.

PNH initial therapy

Disease-severity pathway
- Transfusion and anemia pathway: History of ≥ 1 red blood cell transfusion in the past 24 months and qualifying hemoglobin level.Hemoglobin < 7 g/dL without anemia symptoms or < 9 g/dL with anemia symptoms
- Thrombosis pathway: History of thrombosis.

aHUS Initial Therapy Criteria

Covered when ALL of the following are met for aHUS.

aHUS initial therapy

TMA evidence: Platelet count ≤ 150 × 10^9/L; hemolysis such as an elevation in serum lactate dehydrogenase; and serum creatinine above the upper limits of normal or a requirement for dialysis.
Excluded alternative diagnoses: Documentation that the member does not have ADAMTS13 deficiency or STEC-HUS.

gMG Initial Therapy Criteria

Covered when ALL of the following are met for gMG.

gMG initial therapy: Diagnosis of gMG; prescribed by or in consultation with a neurologist; age ≥ 18 years; baseline MG-ADL score ≥ 6; MGFA Class II to IV; positive serologic test for anti-AChR antibodies; failure of a corticosteroid, unless contraindicated or associated with clinically significant adverse effects; failure of a cholinesterase inhibitor, unless contraindicated or associated with clinically significant adverse effects; and failure of two immunosuppressive therapies, unless contraindicated or associated with clinically significant adverse effects.Dose does not exceed 900 mg per week for the first 4 weeks, followed by 1,200 mg for the fifth dose 1 week later, then 1,200 mg every 2 weeks thereafter.

NMOSD Initial Therapy Criteria

Covered when ALL of the following are met for NMOSD.

NMOSD initial therapy

Recurrent-relapse history
- History of at least two relapses during the previous 12 months.
- History of three relapses during the previous 24 months.

PNH/aHUS Continuation Criteria

Covered when ALL of the following are met for continued PNH or aHUS therapy.

PNH/aHUS continuation: The member is currently receiving medication through the Centene benefit or previously met all initial approval criteria; the member is responding positively to therapy; and, if the request is for a dose increase, the new dose remains within the applicable limit.PNH: dose increase does not exceed 900 mg every 2 weeks. aHUS: dose increase does not exceed 1,200 mg every 2 weeks.

Positive response may include improved hemolysis, reduced transfusion need, increased or stabilized hemoglobin, less fatigue, improved quality of life, or fewer thrombotic events for PNH; or improved hemolysis, increased or stabilized platelet counts, improved or stabilized creatinine/eGFR, or reduced dialysis for aHUS.

gMG Continuation Criteria

Covered when ALL of the following are met for continued gMG therapy.

gMG continuation: The member is currently receiving medication through the Centene benefit or previously met all initial approval criteria and has a 2-point reduction in MG-ADL total score.If the request is for a dose increase, the new dose does not exceed 1,200 mg every 2 weeks.

NMOSD Continuation Criteria

Covered when ALL of the following are met for continued NMOSD therapy.

NMOSD continuation: The member is currently receiving medication through the Centene benefit or previously met all initial approval criteria; the member is responding positively to therapy; Soliris is not prescribed concurrently with rituximab, Enspryng, or Uplizna; and, if the request is for a dose increase, the new dose remains within the dose limit.Dose increase does not exceed 1,200 mg every 2 weeks.

Positive response includes improvement or stabilization in relapse frequency, EDSS, or visual acuity.

Other Diagnoses or Indications Continuation Criteria

Other diagnoses or indications may be continued when criterion 1 or criterion 2 applies.

Other diagnoses/indications continuation

Criterion 1: The member is currently receiving medication through the Centene benefit and documentation supports a positive response to therapy.Approval duration is the duration of the request or 6 months, whichever is less.
Criterion 2: Refer to the off-label use policy for the relevant line of business when the diagnosis is not specifically listed under the diagnoses or indications for which coverage is not authorized.
Use CP.CPA.09 for commercial, HIM.PHAR.21 for the health insurance marketplace, or CP.PMN.53 for Medicaid.

Coverage is not authorized for Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS), because Soliris is not indicated for this condition. Coverage is also not authorized for non-FDA-approved indications that are not supported under the applicable off-label use policy or evidence of coverage.

For neuromyelitis optica spectrum disorder (NMOSD), Soliris must not be prescribed concurrently with rituximab, Enspryng, or Uplizna. This restriction applies to both initial and continued therapy requests.

Antiphospholipid syndrome is excluded from coverage. Use of Soliris for this indication is considered investigational.

Unspecified nephritic syndrome with other morphologic changes is excluded from coverage. Use of Soliris for this indication is considered investigational.

Use of Soliris for antiphospholipid syndrome and unspecified nephritic syndrome with other morphologic changes is considered investigational because conclusive, evidence-based data from randomized controlled trials are lacking. The policy identifies anticoagulation therapy as an alternative for antiphospholipid syndrome and immunosuppression, such as prednisone or mycophenolate mofetil, as an alternative for unspecified nephritic syndrome with other morphologic changes.

Codes and Clinical Thresholds

Not Covered DiagnosesICD-10Not Covered

D68.61

Antiphospholipid syndrome

Not Covered DiagnosesICD-10Not Covered

N05.8

Unspecified nephritic syndrome with other morphologic changes

HCPCS CodesHCPCS

J1300

Injection, eculizumab 10 mg

PNH PNH-Cell Clone Threshold

CriterionFlow cytometry shows detectable GPI-deficient hematopoietic clones or at least 10% PNH cells.

ConditionApplies to initial PNH coverage after a PNH diagnosis.

EvidenceThe result must be documented by flow cytometry.

PNH Anemia Without Symptoms

Hemoglobin thresholdBelow 7 g/dL.

Symptom statusApplies to members without anemia symptoms.

Authorization and Documentation Requirements

Prior Authorization

Initial Authorization

For initial authorization, submit documentation showing that the member meets all applicable initial approval criteria for the requested indication, including diagnosis, prescriber specialty, age, clinical findings, treatment history, dosing, and any required exclusions or contraindications.

Approval duration is 6 months for PNH, aHUS, gMG, and NMOSD.
Initial dosing must remain within the indication-specific limits in the policy.

Prior Authorization

Continuation Authorization

For continuation authorization, document that the member is currently receiving Soliris through the applicable benefit or previously met all initial approval criteria, and that the member is responding positively to therapy.

For PNH and aHUS, document indication-specific laboratory, transfusion, dialysis, or other clinical improvement.
For gMG, document a 2-point reduction in the MG-ADL total score.
For NMOSD, document improvement or stabilization in relapse frequency, EDSS, or visual acuity.

Therapy Overview

Eculizumab (Soliris) is a complement inhibitor used in complement-mediated hematologic, renal, neuromuscular, and neuroinflammatory disorders. The policy addresses coverage for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), adult generalized myasthenia gravis (gMG), and adult anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD).

Abbreviations and Clinical Terms

PNH

AbbreviationPNH.

Full termParoxysmal nocturnal hemoglobinuria.

Policy indicationSoliris coverage includes PNH to reduce hemolysis.

aHUS

AbbreviationaHUS.

Full termAtypical hemolytic uremic syndrome.

Policy descriptionThe policy describes aHUS as complement-mediated HUS.

Initial Approval by Indication

PNH Initial Approval Criteria

Initial coverage for PNH requires ALL of the following.

PNH

Disease-severity pathway
- At least 1 red blood cell transfusion in the past 24 months and hemoglobin < 7 g/dL without anemia symptoms or < 9 g/dL with anemia symptoms.
- History of thrombosis.

aHUS Initial Approval Criteria

Initial coverage for aHUS requires ALL of the following.

aHUS

Continuation Approval

Continuation Authorization Criteria

Continuation therapy requires current Centene-benefit receipt or previously satisfied initial criteria and indication-specific positive response.

Continuation authorization: The member is currently receiving Soliris through the Centene benefit or previously met all initial approval criteria and demonstrates a positive response appropriate to the indication.PNH: dose increases up to 900 mg every 2 weeks. aHUS, gMG, and NMOSD: dose increases up to 1,200 mg every 2 weeks.

For PNH, aHUS, gMG, and NMOSD, the applicable indication-specific response criteria must be documented. For other diagnoses, approval may be for the requested duration or 6 months, whichever is less, when positive response is documented.

Required Prior Therapies

Step	Indication	Required prior therapy	Failure or exception
1	Generalized myasthenia gravis (gMG)	One corticosteroid, one cholinesterase inhibitor, and two immunosuppressive therapies	Each therapy must have failed, unless contraindicated or associated with clinically significant adverse effects

Step	Indication	Required prior therapy	Failure or exception
1	Neuromyelitis optica spectrum disorder (NMOSD)	Rituximab (Rituxan, Ruxience, or Truxima) at up to maximally indicated doses	Rituximab must have failed, unless contraindicated or associated with clinically significant adverse effects; prior authorization is required for rituximab

Dosing and Administration Limits

Soliris for PNH

Weeks 1–4600 mg by IV infusion weekly for the first 4 weeks.

Week 5900 mg for the fifth dose, given 1 week after the fourth dose.

Maintenance900 mg every 2 weeks thereafter.

Soliris for aHUS, gMG, or NMOSD

Weeks 1–4900 mg by IV infusion weekly for the first 4 weeks.

Week 51,200 mg for the fifth dose, given 1 week after the fourth dose.

Maintenance1,200 mg every 2 weeks thereafter.

Policy Summary

PayerWellcare Hawaii

PolicyEculizumab (Soliris) Coverage Policy

Policy CodePolicy N/A

Change TypeModified

Effective Date03.01.12

Next Review DateN/A

Key ActionSubmit clinical documentation demonstrating that all applicable initial approval criteria are met for the requested indication.

SourceLink

On This Page

The PNH pathway also requires at least 1 red blood cell transfusion in the past 24 months.

PNH Anemia With Symptoms

Hemoglobin thresholdBelow 9 g/dL.

Symptom statusApplies to members with anemia symptoms.

Related historyThe PNH pathway also requires at least 1 red blood cell transfusion in the past 24 months.

aHUS Platelet Count Threshold

Platelet threshold150 x 10^9/L or lower.

Disease contextThis is one required sign of thrombotic microangiopathy for aHUS coverage.

Additional TMA findingsTMA also requires hemolysis and serum creatinine above the upper limit of normal or a dialysis requirement.

gMG Baseline MG-ADL Threshold

Baseline MG-ADL thresholdAt least 6.

IndicationRequired for initial generalized myasthenia gravis coverage.

TimingThe score must be documented at baseline.

gMG MGFA Class Requirement

Required classificationMGFA Class II to IV.

IndicationRequired for initial generalized myasthenia gravis coverage.

Related assessmentThe member must also have a baseline MG-ADL score of at least 6.

NMOSD Recent Relapse Requirement

Recent relapse requirementAt least 1 relapse within the previous 12 months.

IndicationRequired for initial neuromyelitis optica spectrum disorder coverage.

Additional relapse historyThe member must also meet the requirement of at least 2 relapses in 12 months or 3 relapses in 24 months.

NMOSD Relapse History Requirement

Relapse historyAt least 2 relapses during the previous 12 months or 3 relapses during the previous 24 months.

IndicationRequired for initial NMOSD coverage.

Separate recent-relapse requirementThe member must also have experienced at least 1 relapse within the previous 12 months.

NMOSD Baseline EDSS Threshold

Baseline EDSS threshold7 or lower.

IndicationRequired for initial NMOSD coverage.

Related evidenceThe member must have positive serologic testing for anti-AQP4 antibodies.

Continued gMG Response Threshold

Required responseA 2-point reduction in the MG-ADL total score.

Continuation useThis response is required for continued gMG therapy.

Clinical meaningA 2-point reduction is considered a clinically meaningful improvement.

For dose increases, confirm the requested dose does not exceed the applicable maximum of 900 mg every 2 weeks for PNH or 1,200 mg every 2 weeks for aHUS, gMG, and NMOSD.

Note

Off-Label Referral

For diagnoses not specifically addressed by the covered indications or exclusions, refer the request to the applicable off-label use policy for the member’s line of business.

Commercial: CP.CPA.09.
Health insurance marketplace: HIM.PHAR.21.
Medicaid: CP.PMN.53.

Step Therapy

Required gMG Treatment Failures

For gMG, document failure of required prior therapies unless a therapy was contraindicated or caused clinically significant adverse effects.

A corticosteroid.
A cholinesterase inhibitor.
Two immunosuppressive therapies.

Step Therapy

Required NMOSD Rituximab Trial

For NMOSD, document failure of rituximab at up to maximally indicated doses unless rituximab was contraindicated or caused clinically significant adverse effects.

Applicable products include Rituxan, Ruxience, and Truxima.
Document the regimen, dates, response or failure, and the reason for any exception.

Documentation Required

Clinical Documentation

Submit office chart notes, laboratory results, and other clinical records supporting that the member meets every applicable approval criterion.

Records should support the diagnosis, prescriber specialty, age, laboratory findings, disease severity, treatment history, response, dosing, and applicable exclusions.

Documentation Required

PNH Documentation

For PNH requests, document the diagnosis and required clinical qualifications.

Hematologist prescribing or consultation.
Member age of at least 18 years.
Flow cytometry showing detectable GPI-deficient hematopoietic clones or at least 10% PNH cells.
At least 1 red blood cell transfusion in the prior 24 months with hemoglobin below 7 g/dL without anemia symptoms or below 9 g/dL with anemia symptoms, or a history of thrombosis.

Documentation Required

aHUS Documentation

For aHUS requests, document the diagnosis, specialist involvement, age, and evidence of complement-mediated thrombotic microangiopathy.

Hematologist or nephrologist prescribing or consultation.
Member age of at least 2 months.
Platelet count of 150 × 10⁹/L or less, hemolysis such as elevated LDH, and serum creatinine above the upper limit of normal or dialysis requirement.
Documentation that the member does not have ADAMTS13 deficiency or STEC-HUS.

Documentation Required

gMG Documentation

For gMG requests, document the diagnosis, neurologist involvement, disease severity, serology, and prior treatment history.

Member age of at least 18 years and neurologist prescribing or consultation.
Baseline MG-ADL score of at least 6 and MGFA Clinical Classification Class II to IV.
Positive anti-AChR antibody serology.
Failure or documented contraindication or clinically significant adverse effects for a corticosteroid, a cholinesterase inhibitor, and two immunosuppressive therapies.

Documentation Required

NMOSD Documentation

For NMOSD requests, document the diagnosis, neurologist involvement, serology, relapse history, disability status, and rituximab history.

Member age of at least 18 years and neurologist prescribing or consultation.
Positive anti-AQP4 antibody serology.
At least one relapse in the prior 12 months and either at least two relapses in the prior 12 months or three relapses in the prior 24 months.
Baseline EDSS score of 7 or less.
Failure of rituximab at up to maximally indicated doses, unless contraindicated or not tolerated.

Documentation Required

Continuation Documentation

For continuation requests, document current benefit receipt or prior fulfillment of initial criteria and objective clinical response to therapy.

PNH: reduced hemolysis, transfusion need, or fatigue; improved or stabilized hemoglobin; improved quality of life; or fewer thrombotic events.
aHUS: reduced hemolysis or plasma therapy, improved or stabilized platelets or renal function, or reduced dialysis need.
gMG: at least a 2-point reduction in MG-ADL total score.
NMOSD: reduced relapse frequency or improved or stabilized EDSS or visual acuity.

Documentation Required

REMS and Vaccination Documentation

Before and during treatment, document meningococcal vaccination status, required safety monitoring, and participation in the Soliris REMS program.

Vaccinate at least 2 weeks before the first dose when possible and revaccinate according to current medical guidelines.
Document REMS enrollment and required monitoring.

Documentation Required

Document Treatment Response

Capture indication-specific evidence of treatment response in each continuation request.

PNH: reduced hemolysis, transfusion need, fatigue, or thrombotic events; improved quality of life.
aHUS: decreased plasma therapy or dialysis, increased eGFR, and normalized platelet or LDH levels.
gMG: clinically meaningful 2-point reduction in MG-ADL score.
NMOSD: stabilization or reduction in EDSS and reduced relapse activity.

Denial Risk

Monitor for Meningococcal Infection

Monitor patients for early signs of meningococcal infection and arrange immediate medical evaluation when infection is suspected; treat with antibiotics when clinically necessary.

Life-threatening and fatal meningococcal infections may occur despite vaccination.

Denial Risk

Unauthorized Indication

Flag requests for unauthorized indications or uses not covered under this policy.

STEC-HUS.
Antiphospholipid syndrome (D68.61).
Unspecified nephritic syndrome with other morphologic changes (N05.8).
Other non-FDA-approved indications not addressed by this policy, unless supported under the applicable off-label policy or evidence of coverage.

Denial Risk

Failure to Meet Indication Criteria

Identify denial conditions when required indication criteria are not met.

Unsupported diagnosis, age, prescriber specialty, laboratory or serologic findings, disease severity, relapse history, EDSS, MG-ADL, or treatment response.
Missing required PNH transfusion, hemoglobin, thrombosis, or flow-cytometry findings.
Missing required aHUS TMA, hemolysis, renal, ADAMTS13, or STEC-HUS exclusion findings.
Missing required gMG treatment failures or NMOSD rituximab failure, absent an applicable exception.

Denial Risk

Meningococcal Safety Risk

Do not initiate or continue Soliris when there is an unresolved serious Neisseria meningitidis infection or the patient is not currently vaccinated against Neisseria meningitidis, unless the risk of delaying treatment outweighs the infection risk.

Document the clinical rationale for treatment despite an unresolved vaccination issue when applicable.

Denial Risk

Prohibited Concurrent Therapy

For NMOSD, Soliris must not be prescribed concurrently with rituximab, Enspryng, or Uplizna.

Review the medication list and treatment plan before authorization and at continuation review.

Denial Risk

Excluded Investigational Indications

Flag antiphospholipid syndrome and unspecified nephritic syndrome with other morphologic changes as excluded investigational indications.

Antiphospholipid syndrome: D68.61; alternative therapy may include anticoagulation.
Unspecified nephritic syndrome with other morphologic changes: N05.8; alternative therapy may include immunosuppression.

TMA

AbbreviationTMA.

Full termThrombotic microangiopathy.

aHUS evidenceFor aHUS, TMA is evidenced by low platelets, hemolysis, and renal impairment or dialysis.

gMG

AbbreviationgMG.

Full termGeneralized myasthenia gravis.

Policy indicationInitial coverage requires positive anti-AChR serology and MGFA Class II to IV.

NMOSD

AbbreviationNMOSD.

Full termNeuromyelitis optica spectrum disorder.

Policy indicationInitial coverage requires positive anti-AQP4 serology and specified relapse history.

MG-ADL

AbbreviationMG-ADL.

Full termMyasthenia Gravis-Activities of Daily Living.

Response measureA 2-point reduction in the total score is considered clinically meaningful improvement.

MGFA

AbbreviationMGFA.

Full termMyasthenia Gravis Foundation of America Clinical Classification.

Policy rangeInitial gMG coverage requires Class II to IV.

STEC-HUS

AbbreviationSTEC-HUS.

Full termShiga toxin E. coli-related hemolytic uremic syndrome.

Coverage statusSoliris is not indicated for STEC-HUS and coverage is not authorized for this diagnosis.

Aquaporin-4 (AQP-4) Seropositive Status

Serologic statusAQP-4-IgG seropositive status.

Confirmation methodConfirmed using a commercially available cell-binding kit assay.

NMOSD requirementPositive anti-AQP4 serology is required for initial NMOSD coverage.

Clinically Meaningful MG-ADL Improvement

Meaningful improvementA 2-point reduction in the total MG-ADL score.

UseThis is used to document positive response for continued gMG therapy.

Assessment toolThe MG-ADL scale measures activities of daily living in generalized myasthenia gravis.

EDSS

ScaleExpanded Disability Status Scale (EDSS).

Range0 represents no disability and 10 represents death.

NMOSD thresholdInitial NMOSD coverage requires a baseline EDSS score of 7 or lower.

Platelet count ≤ 150 × 10^9/L; hemolysis such as elevated serum LDH; and serum creatinine above the upper limits of normal or dialysis requirement.

Excluded alternative diagnoses: No ADAMTS13 deficiency and no STEC-HUS.

gMG Initial Approval Criteria

Initial coverage for gMG requires ALL of the following.

gMG diagnosis; neurologist involvement; age ≥ 18 years; baseline MG-ADL score ≥ 6; MGFA Class II to IV; positive anti-AChR antibodies; and failure of a corticosteroid, cholinesterase inhibitor, and two immunosuppressive therapies unless contraindicated or associated with clinically significant adverse effects.900 mg weekly for the first 4 weeks, 1,200 mg for the fifth dose 1 week later, then 1,200 mg every 2 weeks thereafter.

NMOSD Initial Approval Criteria

Initial coverage for NMOSD requires ALL of the following.

NMOSD

Recurrent-relapse history
- At least two relapses during the previous 12 months.
- Three relapses during the previous 24 months.

Soliris for PNH

IndicationPNH.

Maximum dose900 mg per dose.

Maintenance scheduleThe PNH maintenance regimen is 900 mg every 2 weeks.

Soliris for aHUS

IndicationaHUS.

Maximum dose1,200 mg per dose.

Maintenance scheduleThe aHUS maintenance regimen is 1,200 mg every 2 weeks.

Soliris for gMG or NMOSD

IndicationsGeneralized myasthenia gravis or neuromyelitis optica spectrum disorder.

Maximum dose1,200 mg per dose.

Maintenance scheduleThe maintenance regimen is 1,200 mg every 2 weeks.